中泰证券指出，把握医药结构性行情，持续关注医药/医疗AI+，基本面有积极变化的轻筹码标的。本周 沪深300上涨0.36%，医药生物下滑0.81%，处于31个一级子行业第21位，本周医疗服务上涨0.22%，化 学制药、生物制品、医疗器械、中药、医药商业分别下跌0.54%、0.89%、1.07%、1.75%、2.68%。本周 医药行情分明显，AI医疗、前期回调明显的小核酸相关标的、基本面有边际变化且机构筹码较轻的部 分个股表现亮眼。我们认为医药作为兼具科技和消费属性的板块，在市场行情的轮动中将持续呈现结构 性行情，关于科技属性，创新药板块已经历了过去一年来的急涨后回调，相比2025年年初的位置，普遍 标的估值合理，因此建议关注所在细分行业（优选小核酸、体内CAR、ADC、二代IO、protac等）及公 司本身基本面有边际变化且持续性有望兑现的标的，医药/医疗AI+则是近期热度持续高涨的新方向，除 关注赛道龙头外，建议关注主营业务非医药/医疗AI+相关，但积极拥抱相关技术并预期能够中短期内兑 现估值弹性的标的；消费方面，目前2025年业绩预告基本发布完成，基本体现在当下股价，建议关注中 药、医美等消费医疗板块中积极 ...

证券日报网2月25日讯，前沿生物在接受调研者提问时表示，公司早在数年前便聚焦小核酸赛道，核心 是看好该领域的临床应用与市场前景，立项及平台开发的核心逻辑围绕两大维度展开。一是始终聚焦产 品的潜在临床价值与差异化竞争力，在管线立项时，重点评估产品在疗效、安全性、给药频率等方面相 较于现有药物及其他在研药物是否具备显著差异化优势，同时考量适应症的市场空间与未满足的临床需 求。二是确保管线布局与公司内生能力高度契合，公司拥有20余年多肽药研发经验，尤其在长效递送技 术方面的积累可在小核酸药物研发中复用，为公司快速切入小核酸领域、开展递送技术探索奠定了坚实 基础。此外，公司通过艾可宁的成功研发，打造了从早期立项、非临床研究到药学、注册申报的完整研 发体系，团队对新药研发全流程具备深刻理解与高效执行力，能够保障管线项目快速推进。公司也期待 在不久的将来，能够与各位投资人分享公司在该领域取得的新进展与新成果。 ...

Investment Rating - The industry investment rating is maintained at "Overweight" [7] Core Insights - The report highlights the continuous upgrading of policies in the Heilongjiang biomanufacturing industry, focusing on innovative traditional Chinese medicine and innovative medical devices [4] - The report emphasizes the significant revisions to the Drug Administration Law, which provides institutional support for pharmaceutical innovation and high-quality development [4] - The report identifies three major transformations in China's innovative drug business development (BD) in 2026: technology output combined with product authorization, platform cooperation, and global parallel innovation [8] Summary by Sections Industry Performance - Over the past 12 months, the industry has shown a relative return of -7.06% compared to the CSI 300 index, with an absolute return of 11.53% [3] Investment Highlights - The report notes that BD transactions in the pharmaceutical sector are focused on unmet clinical needs, technological differentiation, and global value [6] - Key areas of focus include oncology therapies such as dual antibodies, ADCs, and TCE combinations, with significant financial agreements highlighted, such as a $650 million upfront payment for a PD-1/VEGF dual antibody [6] - The metabolic disease sector is centered on long-acting GLP-1 and small nucleic acid precision therapies, with notable collaborations resulting in substantial upfront payments and potential total amounts [6] Company-Specific Developments - Companies like Andover Pharmaceuticals and Frontier Biotech have secured significant collaborations with major pharmaceutical firms, indicating a trend towards platform-based cooperation and technology output [7] - Specific collaborations include a $1.05 billion deal for a CTLA-4 inhibitor and a $400 million agreement for small nucleic acid drugs, showcasing the growing interest in innovative therapies [7] - The report suggests monitoring companies such as Rebio Biotech and WuXi AppTec for their advancements in small nucleic acids and platform capabilities [8]

智通财经记者 | 黄华 智通财经编辑 | 谢欣 2月24日，前沿生物公告称，与跨国药企葛兰素史克（GSK）达成独家授权许可协议，授予其两款小核 酸（siRNA） 管线产品在全球范围内的独家开发、生产及商业化权利，其中一款候选药物已进入新药 临床试验申请（IND）阶段，另一款尚在临床前阶段。 根据协议，前沿生物将获得4000万美元首付款及1300万美元近期里程碑付款，还将额外在两个项目中累 计获得最高9.5亿美元的里程碑付款。 前沿生物将负责两款在研产品的早期开发工作，包括其中一款产品在中国的I期临床试验推进，以及另 一款产品的临床试验申请支持性研究；葛兰素史克将负责两款产品之后所有的全球临床开发、监管申报 及商业化活动。 此番分工可能也意味着，若是授权产品未能达到前述预期阶段，葛兰素史克也不会推进后续开发。 前沿生物提出，与葛兰素史克达成此授权合作，将为公司带来首付款及后续里程碑付款，有助于改善现 金流，但合作后续进展与最终能实际收获的授权金额存在不确定性。 沿生物业绩情况 制图：智通财经记者 黄华 2月24日，前沿生物涨停开盘，开盘报27.12元/股，但随后股价下跌。截至2月24日收盘，该公司报收 24.7 ...

Investment Rating - The report maintains a "Recommended" rating for the pharmaceutical industry [5] Core Insights - The underlying logic of the current pharmaceutical industry era is innovation and international expansion, with a focus on innovative drugs and technology-driven sectors [2][3] - The report highlights the strong performance of the CRO market and suggests a dual investment strategy focusing on both "0 to 1" technology innovation and low-position stocks [2][3] - The report emphasizes the ongoing trend of BD (Business Development) transactions in innovative drugs, with significant growth expected in 2026 [4][15] Summary by Sections 1. Key Events in the Pharmaceutical Industry During the Spring Festival - Innovative drug BD transactions have seen a strong start, with significant overseas development and registration progress for key products [13][14] - The total amount of BD transactions for innovative drugs in China for 2026 has already surpassed one-third of the total for 2025 [15] - The revision of the National Essential Medicines List Management Measures may signal changes in the essential medicines directory [28] 2. Pharmaceutical Market Review and Hotspot Tracking - The pharmaceutical sector's performance was relatively weak, with a weekly decline of 0.81%, ranking 20th among all industries [34][38] - The total trading volume for pharmaceuticals was 401.12 billion yuan, accounting for 3.83% of the total market, below the historical average of 7.09% [55] - The report notes a rising valuation level for the pharmaceutical industry, with a PE ratio of 29.25, which is below the historical average [52] 3. Stock Performance Review - The report lists the top-performing stocks, including Dongyangguang and Zhendemedical, while highlighting the underperformers like Huayuan Biology and *ST Sailong [58][59]

Investment Rating - The industry maintains a "Neutral" rating, with specific company ratings of "Buy" for Heng Rui Pharmaceutical (600276) and "Increase" for WuXi Biologics (603259) [46] Core Insights - The recent national drug procurement has been stable, with active participation from companies and continued benefits for patients [8][9] - The issuance of the "National Basic Drug Directory Management Measures" aims to enhance the management of essential medicines [10][11] - Heng Rui Pharmaceutical reported positive top-line results for its GLP-1/GIP dual receptor agonist, indicating significant weight loss in clinical trials [12] - The approval of Mu Feng Da® for the treatment of adult type 2 diabetes marks a significant development in the market [12] Industry News - The national drug procurement involved 316 commonly used drugs across 26 therapeutic areas, with a high participation rate from over 5,100 medical institutions and 1,091 companies [8][9] - The procurement process has been standardized, allowing companies to bid online once for nationwide sales, significantly reducing costs [9] - The management measures for the national basic drug directory have been revised to include legal policy bases and optimize the directory structure [10][11] Company Announcements - Innovent Biologics has entered a global strategic partnership with Eli Lilly to advance new drug development in oncology and immunology [26] - Kelun Pharmaceutical's TROP2 ADC has received approval for a fourth indication from the NMPA [27] - Heng Rui Pharmaceutical's drug has been included in the list of breakthrough therapy products, and its application for marketing approval has been accepted for priority review [28] - WuXi Biologics has forecasted a positive earnings outlook, expecting a revenue increase of approximately 16.7% [30] Market Review - The Shanghai Composite Index rose by 1.43%, while the Shenzhen Component Index increased by 2.37%, with the SW Pharmaceutical and Biotech Index up by 0.23% [36] - The industry’s price-to-earnings ratio (TTM) stands at 51.17, with a valuation premium of 259% compared to the CSI 300 [40] Weekly Strategy - The report suggests focusing on investment opportunities in innovative drugs, CXO, and upstream life sciences, while also monitoring performance recovery indicators [46]

Summary of Industry Reports Industry: Pharmaceutical and Biotechnology Key Points from Document 1 1. **Raw Material Supply Changes**: The supply of raw materials is accelerating, with a focus on subsequent volume and price changes [1] 2. **Global GLP-1 Landscape**: The global GLP-1 landscape is continuously evolving, and Chinese companies are still pursuing international expansion [1] 3. **Small Nucleic Acid Sector**: Leading companies are gradually entering the small nucleic acid field, with market progress expected to drive the development of supporting industrial chains [1] 4. **Retail Pharmaceutical Market Outlook**: The retail pharmaceutical market is expected to improve by Q4 2025, with an enhanced positioning of chain pharmacies [1] 5. **Value of Oral Immunomodulatory Drugs**: Emphasis on the market value of oral immunomodulatory drugs [1] 6. **Investment Recommendations**: Recommended companies include Chuaning Biological, with attention to Lianbang Pharmaceutical, Guobang Pharmaceutical, and Puluo Pharmaceutical, as well as synthetic biology companies [1] 7. **CXO Order Trends**: Positive trends in CXO orders and rising prices for safety evaluation orders, with recommendations for Yinos and Zhaoyan New Drug, and recommendations for Weiya Biological and Puris [1] Key Points from Document 2 1. **Small Nucleic Acids Breakthrough**: Continuous breakthroughs in small nucleic acids, with ongoing progress in external authorizations by Chinese companies, recommending Yuekang Pharmaceutical and Sunshine Novo [2] 2. **Self-Immunity Field**: Focus on breakthroughs in oral directions and difficult-to-treat areas like UC/IBD, recommending Yahong Pharmaceutical and Yifang Biological [2] 3. **GLP-1 Weight Loss Authorizations**: Recommendations for Zhongsheng Pharmaceutical in the GLP-1 weight loss field, with attention to Lianbang Pharmaceutical and Shiyao Group [2] 4. **ZAP-X Radiation Therapy Equipment**: Initiation of domestic clinical research for ZAP-X radiation therapy equipment, recommending Baiyang Pharmaceutical [2] 5. **Policy Support for Brain-Computer Interface Technology**: Support for the development of invasive brain-computer interfaces, recommending Meihao Medical and Botuo Biological, with accelerated approvals for non-invasive devices, focusing on Xiangyu Medical and Kefu Medical [2] 6. **High-Value Medical Device Exports**: Breakthroughs in exports of high-value medical consumables, with attention to Chunli Medical, Aikang Medical, Nanwei Medical, and Baixin An [2] 7. **AI in Healthcare**: Accelerated applications of AI in healthcare, reshaping application scenarios and bringing changes in industrial chain value, recommending Anbiping and focusing on Yuyue Medical and Meinian Health [2] 8. **Chain Pharmacy Industry**: Industry consolidation in chain pharmacies, with policy support for enhanced positioning, recommending Yifeng Pharmacy and Laobaiqing, with attention to Yixintang [2]

Macro and Strategy Research - In January 2026, the central bank's liquidity net injection reached 1.2 trillion yuan, an increase of nearly 400 billion yuan compared to December 2025, indicating a supportive stance on liquidity [3] - The issuance of interest rate bonds in January 2026 totaled 2.7 trillion yuan, a year-on-year increase of over 600 billion yuan, with significant growth in government bonds, local bonds, and policy financial bonds [4] - The bond market outlook suggests that if the liquidity remains stable, interest rate bonds may show a strong oscillation pattern, with a focus on 3-year bonds and ultra-long-term bonds for potential gains [5] Industry Research - The pharmaceutical and biotechnology industry is seeing a concentration of performance forecasts, with key developments including the approval of new drugs and significant partnerships among companies [10][11] - The SW pharmaceutical and biotechnology index saw a decline of 0.97% in the week of January 30 to February 5, 2026, with the industry’s price-to-earnings ratio at 51.01 times, reflecting a 261% premium over the CSI 300 index [11] - The report suggests focusing on investment opportunities in innovative drugs, CXO, and upstream life sciences, as well as monitoring companies that are expected to show a turnaround in performance [12]

医药周报 20260208: 【国联民生医药】小核酸风口之上：四重催化密集 glmszqdatemark 医药行情回顾&分析&近期判断 行情回顾：当周（2.2-2.6）医药生物指数环比 0.14%，跑赢创业板指数和沪深 300 指数。在所有行业中，当周（2.2-2.6）医药涨跌幅排在第 14 位。医药在周一大 跌后，本周后面都是在演绎修复。结构上看，创新链条，A 股部分辨识度个股表 现不错，CRO 及部分上游条线表现较好。非创新药方面，消费医疗、中药也有一 定表现，表现从创新聚焦开始发散。医药成交总额 4755.06 亿元，沪深总成交额 为 119319.07 亿元，医药成交额占比沪深总成交额比例为 3.99%（2013 年以来 成交额均值为 7.09%）。 原因分析：医药整体不在市场重心，仍然是散点行情为主，同时内部切换特征也 比较明显，创新条线走发散逻辑，CRO 及部分上游表现较好。非创新药方面，受 市场整体消费表现较好带动，消费医疗部分表现相对较强，中药因政策刺激周五 表现较好，在行业普遍表现一般的状态下相对表现较好。近期重磅 BD，从走势反 馈角度，还在消化筹码，产业逻辑依旧强劲，核心标的逐步进入价值 ...

Group 1 - The core viewpoint of the article highlights the recent performance of the Kexin Innovation Drug ETF (589720), which has seen a net inflow of over 1 billion yuan in the past 20 days, indicating a focus on theme-based investment opportunities in the pharmaceutical sector [1] - The pharmaceutical sector currently lacks a clear investment theme, with innovative drugs undergoing a phase of profit realization and adjustment, suggesting that future opportunities will revolve around thematic investments such as brain-computer interfaces, AI healthcare, and small nucleic acids [1] - The raw material drug sector is emphasized as being at a bottoming phase, with potential for mid-term cyclical improvement driven by rising prices in chemicals and the introduction of new businesses like small nucleic acids, peptides, and ADCs [1] Group 2 - The Kexin Innovation Drug ETF (589720) tracks the Kexin Innovation Drug Index (950161), which focuses on the research, development, and production of innovative drugs, with a daily price fluctuation limit of 20% [1] - The index emphasizes high growth and innovation within the biopharmaceutical industry, reflecting the performance and market value of companies engaged in new drug development [1] - The raw material and intermediate drug industry has experienced a 4-5 year price decline, but with the recent rise in commodity and upstream chemical prices, there is an expectation for price improvement and stabilization in the market [1]